By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer's disease in a recent proof-of-concept clinical trial.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130409005199&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130409005199&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment